TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06433765: A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

Sponsor: TG Therapeutics, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 728 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT06433765 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06433765 Rescue Dossier →